Announcements
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Development of a New Formulation with the Potential to Increase Biological Activity, Patient Convenience and Commercial Opportunity –…
Read MoreAtopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 Excerpt from the Press Release: BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the…
Read More– GMAB ADC demonstrated highly targeted delivery to tumor cells and durable tumor regression in preclinical model of colorectal cancer – – Results presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 – Excerpt from the Press Release: HOPEWELL, N.J.–(BUSINESS WIRE)–Gennao Bio, a privately held genetic medicines company developing…
Read MoreExcerpt from the Press Release: Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, have announced the initiation of its Phase 1 study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF). COR-1167 is a once-daily…
Read MoreCompany advances towards their second clinical trial for SynKIR™ platform treating patients with Diffuse Large B Cell Lymphoma and other B-cell Non-Hodgkin Lymphoma subtypes who are relapsed or refractory after standard of care, including CAR T therapies Excerpt from the Press Release: PHILADELPHIA, April 3, 2024 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR T company developing…
Read MoreCompany Announces Opening of a Second R&D site in Philadelphia, PA, and the Appointments of Shelley Allen as Head of Drug Discovery, and Munir Mosaheb as Head of Biology Excerpt from the Press Release: PHILADELPHIA–(BUSINESS WIRE)–Nimble Therapeutics today announced the opening of a second R&D site in Philadelphia, PA. The new site, located in B+Labs,…
Read MoreExcerpt from the Press Release: Viking Therapeutics have announced positive results from the company’s Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity.…
Read MoreExcerpt from the Press Release: NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus…
Read MoreInitiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024 Excerpt from the Press Release: CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by…
Read MoreDeep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination – – Phase 1 portion of the Phase 1/2a trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IMM-6-415 and establish a candidate recommended…
Read More